Expand BGNE Menu
BGNE MENU

BGNE Stock Posts


BGNE stock declines -9.0% in premarket,

Premarket Decliner

BGNE Beigene Ltd. - American Depositary Shares208.12-4.07-1.9%

Premarket:189.47-18.65 (-9.0%)

BeiGene Highlights Significant BRUKINSA (zanubrutinib) Data at the 17th International Conference on Malignant Lymphoma

Business WireThu, 15-Jun 3:00 AM
Unusual Option Volume

BGNE Beigene Ltd. - American Depositary Shares243.12-35.31 (-12.7%)

Beigene Ltd. - American Depositary Shares trades 2,691 contracts. The company has the following event: on Jul 12, 2022. News: BeiGene Announces Closing of Its RMB22.2 Billion (US$3.5 Billion) Initial Public Offering on the STAR Market of the Shanghai Stock Exchange in China
View Details...
BGNE #BeigeneAds stock declines -2.5% in after hours trading. See the latest news.

After Hours Decliner

BGNE Beigene Ads164.06+5.71+3.6%

After Hours:160.00-4.06 (-2.5%)

BeiGene Reports Fourth Quarter and Full Year 2019 Financial Results

Globe NewswireMon, 2-Mar 4:05 PM
BGNE #BeigeneAds stock declines -2.5% in after hours trading. See the latest news.

After Hours Decliner

BGNE Beigene Ads164.06+5.71+3.6%

After Hours:160.00-4.06 (-2.5%)

BeiGene Reports Fourth Quarter and Full Year 2019 Financial Results

Globe NewswireMon, 2-Mar 4:05 PM
BGNE #BeigeneAds stock increases 3.4% after hours.

After Hours Gainer

BGNE Beigene Ads196.40-0.90-0.5%

After Hours:203.00+6.60 (+3.4%)

U.S. FDA Grants BeiGene's BRUKINSA (zanubrutinib) Accelerated Approval to Treat Adult Patients with Mantle Cell Lymphoma Who Received at Least One Prior Therapy

Globe NewswireThu, 14-Nov 4:20 PM
BGNE #BeigeneAds stock increases 2.9% after hours.

After Hours Gainer

BGNE Beigene Ads196.40-0.90-0.5%

After Hours:202.00+5.60 (+2.9%)

U.S. FDA Grants BeiGene's BRUKINSA (zanubrutinib) Accelerated Approval to Treat Adult Patients with Mantle Cell Lymphoma Who Received at Least One Prior Therapy

Globe NewswireThu, 14-Nov 4:20 PM
Load Earlier Posts